Prurigo nodularis
Conditions
Interventions
Systemic drug therapy observation group:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosis of nodular prurigo by 2 or more dermatologists (including papular, nodular, and plaque types); 2. Duration of diagnosed nodular prurigo >= 3 months (presence of nodular prurigo lesions for more than 3 months); 3. Age >= 18 years, no gender restriction; 4. Severity assessment of PN reaches moderate to severe (i.e., number of skin nodules >= 20, and itching pp-NRS score > 4), requiring systemic drug treatment as determined by a physician (including new targeted drugs, traditional immunosuppressants, and traditional anti-inflammatory antipruritic drugs); 5. Able to undergo long-term regular follow-up; 6. Agree to participate in this project and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Other diseases characterized by nodular skin lesions, such as actinic prurigo, hypertrophic lichen planus, acquired reactive penetrating collagenosis, prurigo-like pemphigus, prurigo-like dystrophic epidermolysis bullosa, and scabies nodules; 2.Participants currently enrolled in other clinical research projects; 3.Participants who are unable to understand or cooperate with the follow-up procedures of this project.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pruritus pp-NRS4 achievement rates;IGA 0/1 achievement rate for skin lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage decrease in pruritus pp-NRS and SD-NRS scores from baseline;Percentage decrease in IGA score from baseline;Disease remission rate (remission defined as pruritus pp-NRS score < 4 and nodular skin lesions < 5, lasting for more than 3 months);Percentage decrease in DLQI score from basel; | — |
Countries
China
Contacts
Public ContactXia Dou
Peking University Shenzhen Hospital
Outcome results
None listed